全文获取类型
收费全文 | 63009篇 |
免费 | 4534篇 |
国内免费 | 1611篇 |
专业分类
耳鼻咽喉 | 94篇 |
儿科学 | 1437篇 |
妇产科学 | 673篇 |
基础医学 | 3020篇 |
口腔科学 | 501篇 |
临床医学 | 8069篇 |
内科学 | 20835篇 |
皮肤病学 | 181篇 |
神经病学 | 733篇 |
特种医学 | 1572篇 |
外国民族医学 | 9篇 |
外科学 | 7925篇 |
综合类 | 10719篇 |
现状与发展 | 3篇 |
预防医学 | 2427篇 |
眼科学 | 85篇 |
药学 | 6111篇 |
48篇 | |
中国医学 | 3384篇 |
肿瘤学 | 1328篇 |
出版年
2024年 | 43篇 |
2023年 | 996篇 |
2022年 | 1316篇 |
2021年 | 2287篇 |
2020年 | 2380篇 |
2019年 | 2161篇 |
2018年 | 2067篇 |
2017年 | 2036篇 |
2016年 | 2092篇 |
2015年 | 2194篇 |
2014年 | 4382篇 |
2013年 | 4670篇 |
2012年 | 3573篇 |
2011年 | 4147篇 |
2010年 | 3291篇 |
2009年 | 3366篇 |
2008年 | 3260篇 |
2007年 | 3344篇 |
2006年 | 2993篇 |
2005年 | 2731篇 |
2004年 | 2098篇 |
2003年 | 1828篇 |
2002年 | 1527篇 |
2001年 | 1418篇 |
2000年 | 1085篇 |
1999年 | 910篇 |
1998年 | 758篇 |
1997年 | 694篇 |
1996年 | 664篇 |
1995年 | 611篇 |
1994年 | 605篇 |
1993年 | 433篇 |
1992年 | 386篇 |
1991年 | 395篇 |
1990年 | 313篇 |
1989年 | 316篇 |
1988年 | 292篇 |
1987年 | 212篇 |
1986年 | 181篇 |
1985年 | 196篇 |
1984年 | 159篇 |
1983年 | 94篇 |
1982年 | 112篇 |
1981年 | 99篇 |
1980年 | 92篇 |
1979年 | 85篇 |
1978年 | 61篇 |
1977年 | 56篇 |
1976年 | 49篇 |
1975年 | 28篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
目的探讨前瞻性护理干预在急性心力衰竭患者中的应用效果。方法选取2018年4月—2020年5月河南省某医院收治的122例急性心力衰竭患者为研究对象,采用随机数字表法分为观察组与对照组,每组61例。对照组患者采用常规护理,观察组患者采用前瞻性护理,比较2组患者的干预效果、并发症发生情况,干预前后焦虑自评量表(SAS)、抑郁自评量表(SDS)评分及护理满意度。结果观察组患者干预总有效率为95.08%,高于对照组的75.41%,差异有统计学意义(χ2=9.385,P=0.002)。观察组患者并发症发生率为3.28%,低于对照组的18.03%,差异有统计学意义(χ2=6.974,P=0.008)。2组患者干预后SAS及SDS评分均低于干预前,且观察组低于对照组,差异均有统计学意义(P<0.05)。观察组患者护理满意度为98.36%,高于对照组的86.89%,差异有统计学意义(χ2=4.319,P=0.038)。结论前瞻性护理干预用于急性心力衰竭患者,有助于改善患者负性情绪及减少并发症的发生。 相似文献
3.
轻度认知障碍(Mild cognition impairment, MCI)是尚未达到阿尔兹海默病(Alzheimer’s disease, AD)的诊断标准且可逆转为正常脑老化状态的最佳窗口期。情志异常、肝失疏泄(肝失疏泄日久致肝郁)已被证实为MCI的重要情志病机,且“长期负性情绪积累肝失疏泄致衰加速脑老化”的科学假说已在本课题组前期研究中得到初步证实,疏肝法干预肝郁型MCI患者疗效显著,但以上作用机制尚未得到完全阐述。因此本研究系统总结了中医学对MCI的认识,长期情绪不调肝失疏泄对MCI的影响及可能机制,疏肝解郁方药及其成分改善肝郁型MCI的可行性,并提出使用无束缚性设计的眼动技术以探索疏肝法改善肝郁型MCI的可行性,为MCI的中医药干预及其神经机制探讨提供新思路,为中医情志衰老学说增添新内涵。 相似文献
4.
5.
6.
7.
《Journal of vascular and interventional radiology : JVIR》2022,33(9):1034-1044.e29
PurposeTo assess the safety and tolerability of a vandetanib-eluting radiopaque embolic (BTG-002814) for transarterial chemoembolization (TACE) in patients with resectable liver malignancies.Materials and MethodsThe VEROnA clinical trial was a first-in-human, phase 0, single-arm, window-of-opportunity study. Eligible patients were aged ≥18 years and had resectable hepatocellular carcinoma (HCC) (Child-Pugh A) or metastatic colorectal cancer (mCRC). Patients received 1 mL of BTG-002814 transarterially (containing 100 mg of vandetanib) 7–21 days prior to surgery. The primary objectives were to establish the safety and tolerability of BTG-002814 and determine the concentrations of vandetanib and the N-desmethyl vandetanib metabolite in the plasma and resected liver after treatment. Biomarker studies included circulating proangiogenic factors, perfusion computed tomography, and dynamic contrast-enhanced magnetic resonance imaging.ResultsEight patients were enrolled: 2 with HCC and 6 with mCRC. There was 1 grade 3 adverse event (AE) before surgery and 18 after surgery; 6 AEs were deemed to be related to BTG-002814. Surgical resection was not delayed. Vandetanib was present in the plasma of all patients 12 days after treatment, with a mean maximum concentration of 24.3 ng/mL (standard deviation ± 13.94 ng/mL), and in resected liver tissue up to 32 days after treatment (441–404,000 ng/g). The median percentage of tumor necrosis was 92.5% (range, 5%–100%). There were no significant changes in perfusion imaging parameters after TACE.ConclusionsBTG-002814 has an acceptable safety profile in patients before surgery. The presence of vandetanib in the tumor specimens up to 32 days after treatment suggests sustained anticancer activity, while the low vandetanib levels in the plasma suggest minimal release into the systemic circulation. Further evaluation of this TACE combination is warranted in dose-finding and efficacy studies. 相似文献
8.
9.
《European journal of surgical oncology》2022,48(5):956-966
BackgroundA comprehensive re-evaluation on the role of trans-arterial chemoembolization (TACE) in patients with intrahepatic cholangiocarcinoma.MethodsA thorough database searching was performed in PubMed, EMBASE, and the Cochrane Library. Eligible studies were restricted to comparative studies between TACE and non-TACE cohorts. RevMan5.3 software and Stata 13.0 software were used for statistical analyses. The primary endpoint of our study was long-term survival.ResultsA total of 11 studies with 2036 patients were finally identified. Pooled results revealed that patients receiving TACE had a significantly better overall survival (OS) versus those without TACE (P < 0.05). Subgroup analyses were performed according to different types of TACE. Prophylactic post-surgical TACE (PPTACE) was associated with a significantly better OS versus those without PPTACE (P < 0.05). Palliative TACE (PTACE) also achieved a significantly better OS compared with those with supportive treatment (ST) only (P < 0.00001). However, TACE had no impact on disease-free survival (P = 0.87) and was less effective than surgical resection (P = 0.003).ConclusionPPTACE has a remarkable impact on OS versus those with surgical resections only and should be regularly performed. Regarding patients with unresectable disease, apart from conventional ST, adjuvant PTACE is also recommended. Upcoming prospective randomized controlled trials are warranted for further validation. 相似文献
10.